Shareholders to Vote on Massive Reverse Stock Split and Authorized Share Increase to Facilitate Obsidian Merger

summarizeSummary

Galera Therapeutics filed a definitive proxy statement detailing proposals for a reverse stock split (1:75 to 1:200) and a doubling of authorized shares, both critical steps to enable its merger with Obsidian Therapeutics and a $350 million private placement.

check_boxKey Events

• Reverse Stock Split Proposal

  Shareholders will vote on a reverse stock split at a ratio between 1:75 and 1:200, a measure explicitly stated as necessary to enable the listing of the combined company's common stock on Nasdaq following the Obsidian merger.

• Authorized Share Increase

  The company proposes to increase authorized common stock from 200 million to 400 million shares to support the conversion of Series B Preferred Stock and the $350 million Concurrent PIPE Financing related to the merger.

• Written Consent Right

  A proposal to amend the charter to permit stockholders to act by written consent aims to streamline and expedite the approval of the Obsidian Merger and related transactions.

• Merger Context

  This proxy statement follows the April 14, 2026 announcement of a definitive merger agreement with privately-held Obsidian Therapeutics in an all-stock transaction, coupled with a $350 million private placement.

auto_awesomeAnalysis

This definitive proxy statement outlines critical proposals for Galera Therapeutics' upcoming annual meeting, directly linked to its recently announced merger with Obsidian Therapeutics and a concurrent $350 million private placement. The proposed reverse stock split, ranging from 1:75 to 1:200, is an aggressive measure necessary to meet Nasdaq listing requirements for the combined entity, signaling severe financial distress and a need to avoid delisting. The doubling of authorized common stock from 200 million to 400 million shares is intended to facilitate the conversion of preferred stock and the substantial private placement, which will result in significant dilution for existing shareholders. Additionally, the proposal to permit stockholder action by written consent aims to expedite the merger approval process. These actions, while crucial for the company's strategic shift and survival, reflect a highly unfavorable situation for current equity holders.